SLS
$5.17-0.20 (-3.64%)
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a p...
Recent News
SELLAS Life Sciences (SLS) Is Up 18.0% After Positive AML Trial Updates – What’s Changed
In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that its Phase 3 REGAL trial of Galinpepimut-S would continue unchanged after an Independent Data Monitoring Committee review. Taken together, these developments highlight both near-term clinical momentum around SLS009 and growing validation of Galinpepimut-S as a potential maintenance therapy in...
Assessing SELLAS Life Sciences Group (SLS) Valuation After Recent Leukemia Trial Updates
SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for Galinpepimut S. See our latest analysis for SELLAS Life Sciences Group. The recent clinical updates appear to be reflected in momentum, with a 44.8% 1 month share price return, a 217.8% 3 month share price return and a very large 1 year total shareholder return, although the 5 year total shareholder...
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement
SELLAS Life Sciences Group (SLS) has entered an agreement with IMPACT-AML, a pan-European clinical network, to run a new study of its CDK9 inhibitor SLS009 in high-risk newly diagnosed acute myeloid leukemia. See our latest analysis for SELLAS Life Sciences Group. The IMPACT AML agreement comes after a period of sharp moves in SELLAS Life Sciences Group, with a 30 day share price return of 101.47% and a 90 day share price return of 90.28%. The 1 year total shareholder return is 323.75%,...
SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed?
SELLAS Life Sciences Group recently reported that its Phase 3 REGAL trial of galinpepimut‑S (GPS) in Acute Myeloid Leukemia had reached 72 of the 80 overall-survival events required for final analysis as of December 26, 2025, following an earlier recommendation from the Independent Data Monitoring Committee to continue the study without modification. This event-driven trial milestone, combined with SELLAS remaining fully blinded to efficacy data and hosting a detailed AML-focused R&D Day,...
Social Buzz: Wallstreetbets Stocks Advance Premarket Monday; SELLAS Life Sciences Group, Chevron to Open Higher
The most-talked-about stocks in the Reddit subforum Wallstreetbets were advancing hours before Monda